|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2000-6-23
|
|
pubmed:abstractText |
We studied the rate of progression of striatal dopamine transporter function in Parkinson's disease (PD). Eight patients with early PD without antiparkinsonian medication and 7 healthy volunteers were investigated with [18F]CFT positron emission tomography (PET). The PET scan was carried out twice at an approximate 2-year interval. The uptake of [18F]CFT was calculated as a region-cerebellum:cerebellum ratio at 180 to 210 minutes after injection. At the first PET scan, the [18F]CFT uptake in PD patients in the putamen was 1.45 +/- 0.45 (mean +/- SD) (42% of the control mean) and 2.43 +/- 0.59 in the caudate nucleus (76% of the control mean). The ratios declined by the time of the second PET scan, and the rate of annual decline of the baseline mean in PD patients was 13.1% in the putamen and 12.5% in the caudate nucleus. In controls, the corresponding figures were 2.1% for the putamen and 2.9% for the caudate nucleus. The decline in [18F]CFT uptake was significantly higher in PD patients than in controls. Thus, dopamine transporter ligands such as [18F]CFT seem to be sensitive markers for the rate of progression in PD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/(1R-(exo,exo))-3-(4-fluorophenyl)-8-...,
http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cocaine,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Plasma Membrane Transport...,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Uptake Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorine Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Transport Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nerve Tissue Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0364-5134
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
804-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10852547-Aged,
pubmed-meshheading:10852547-Antiparkinson Agents,
pubmed-meshheading:10852547-Brain,
pubmed-meshheading:10852547-Carrier Proteins,
pubmed-meshheading:10852547-Caudate Nucleus,
pubmed-meshheading:10852547-Cerebellum,
pubmed-meshheading:10852547-Cocaine,
pubmed-meshheading:10852547-Disease Progression,
pubmed-meshheading:10852547-Dopamine Plasma Membrane Transport Proteins,
pubmed-meshheading:10852547-Dopamine Uptake Inhibitors,
pubmed-meshheading:10852547-Female,
pubmed-meshheading:10852547-Fluorine Radioisotopes,
pubmed-meshheading:10852547-Humans,
pubmed-meshheading:10852547-Male,
pubmed-meshheading:10852547-Membrane Glycoproteins,
pubmed-meshheading:10852547-Membrane Transport Proteins,
pubmed-meshheading:10852547-Middle Aged,
pubmed-meshheading:10852547-Nerve Tissue Proteins,
pubmed-meshheading:10852547-Parkinson Disease,
pubmed-meshheading:10852547-Putamen,
pubmed-meshheading:10852547-Time Factors,
pubmed-meshheading:10852547-Tomography, Emission-Computed
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
|
|
pubmed:affiliation |
Department of Neurology, University of Turku, Finland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
